Log In
BCIQ
Print this Print this
 

olmutinib (BI 1482694, HM61713)

  Manage Alerts
Collapse Summary General Information
Company Hanmi Pharmaceutical Co. Ltd.
DescriptionThird-generation EGFR mutation-specific tyrosine kinase inhibitor (TKI)
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionEpidermal growth factor (EGF) receptor inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat EGFR T790M mutation-positive non-small cell lung cancer (NSCLC); Treat non-small cell lung cancer (NSCLC)
Regulatory Designation U.S. - Breakthrough Therapy (Treat EGFR T790M mutation-positive non-small cell lung cancer (NSCLC))
PartnerZai Lab Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$50.0M

$680.0M


 Deals Details
Get a free BioCentury trial today